Lung Cancer:: Current Clinical Oncology
Editat de David J. Stewarten Limba Engleză Hardback – 4 mar 2010
Din seria Current Clinical Oncology
- 5%
Preț: 1638.72 lei - 5%
Preț: 698.03 lei - 5%
Preț: 755.47 lei - 5%
Preț: 1543.55 lei - 5%
Preț: 1375.05 lei - 5%
Preț: 1560.37 lei - 5%
Preț: 363.21 lei - 5%
Preț: 1465.74 lei - 5%
Preț: 1538.68 lei - 5%
Preț: 756.94 lei - 5%
Preț: 719.66 lei - 5%
Preț: 754.80 lei - 5%
Preț: 1072.68 lei - 5%
Preț: 758.46 lei - 5%
Preț: 1462.15 lei - 5%
Preț: 1069.77 lei - 5%
Preț: 793.25 lei - 5%
Preț: 752.09 lei - 5%
Preț: 762.85 lei - 5%
Preț: 1073.41 lei - 5%
Preț: 748.74 lei - 5%
Preț: 1542.21 lei - 5%
Preț: 1071.44 lei - 5%
Preț: 1058.42 lei - 5%
Preț: 1900.53 lei - 5%
Preț: 1741.32 lei - 5%
Preț: 1066.08 lei - 5%
Preț: 1763.18 lei - 5%
Preț: 1375.20 lei - 5%
Preț: 1067.90 lei - 5%
Preț: 1563.50 lei
Preț: 1386.42 lei
Preț vechi: 1459.39 lei
-5%
Puncte Express: 2080
Carte tipărită la comandă
Livrare economică 24 august-07 septembrie
Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
Specificații
ISBN-13: 9781607615231
ISBN-10: 1607615231
Pagini: 556
Ilustrații: XVI, 538 p. 30 illus., 14 illus. in color.
Dimensiuni: 160 x 241 x 39 mm
Greutate: 1.09 kg
Ediția:2010
Editura: Humana
Colecția Current Clinical Oncology
Seria Current Clinical Oncology
Locul publicării:Totowa, NJ, United States
ISBN-10: 1607615231
Pagini: 556
Ilustrații: XVI, 538 p. 30 illus., 14 illus. in color.
Dimensiuni: 160 x 241 x 39 mm
Greutate: 1.09 kg
Ediția:2010
Editura: Humana
Colecția Current Clinical Oncology
Seria Current Clinical Oncology
Locul publicării:Totowa, NJ, United States
Public țintă
ResearchCuprins
Molecular Pathology of Lung Cancer.- Tumor Microenvironment.- Racial and Ethnic Diversity in Lung Cancer.- Pharmacogenetics of Lung Cancer.- Lung Cancer Prevention.- Adjuvant and Neoadjuvant Therapy of NSCLC.- Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer.- Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment.- Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer.- Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer.- Angiogenesis Inhibitors in Lung Cancer.- Other Molecular Targeted Agents in Non-small Cell Lung Cancer.- Vaccine Therapy for Lung Cancer.- Gene-Based Therapies for Lung Cancer.- Lung Cancer Resistance to Chemotherapy.- Small Cell Carcinoma of the Lung.- Mesothelioma.- Advances in Oncology Clinical Research: Statistical and Study Design Methodologies.- Palliative Care for Patients with Lung Cancer.- The Future of Lung Cancer.
Recenzii
From the reviews:
“This comprehensive review of prevention and treatment strategies for malignancies of the thorax thoroughly investigates tumor biology and discusses established and emerging therapies. … The book is written for a wide audience that includes pathologists, pulmonologists, medical oncologists, radiation oncologists, and surgical oncologists. … I would highly recommend this book to anyone interested in current and future therapies for lung cancer. This is one of the most comprehensive and up-to-date accounts of the field.” (Nagendra S. Koneru, Doody’s Review Service, July, 2010)
“This comprehensive review of prevention and treatment strategies for malignancies of the thorax thoroughly investigates tumor biology and discusses established and emerging therapies. … The book is written for a wide audience that includes pathologists, pulmonologists, medical oncologists, radiation oncologists, and surgical oncologists. … I would highly recommend this book to anyone interested in current and future therapies for lung cancer. This is one of the most comprehensive and up-to-date accounts of the field.” (Nagendra S. Koneru, Doody’s Review Service, July, 2010)
Textul de pe ultima copertă
This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention.Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment.
Caracteristici
Provides full coverage of established and emerging therapies, including novel targeted and antiangiogenic agents Evaluates the mechanisms of drug resistance and the therapeutic potential of new targets Integrates molecular biology into strategies for prevention and treatment of lung cancer Includes supplementary material: sn.pub/extras